Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Silverii 2021
GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models
With a number of GLP-1 medications in Phase 2 trials, we believe that the winning formula to stand out in a crowded landscape will be to combine medication with advanced behavior change to drive differentiated outcomes, while proving it with Phase 4 studies
GLP-1 receptor agonists frequently cause nausea, vomiting, and diarrhea, especially during treatment initiation
For someone with moderate risk, early metabolic dysfunction, family history, preserving cognition may tip the scale
US$ 23.41
US$ 28.36
US$ 29.62
US$ 28.51
US$ 25.82
